Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy

Introduction: Data on the efficacy and risk of curative-intent chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer (NSCLC) and interstitial lung disease (ILD) are limited. The aim of this study was to explore the impact of ILD classification on acute exacerbation (AE) of ILD and prognosis in patients with stage III NSCLC and ILD treated with chemoradiotherapy. Materials and methods: We retrospectively reviewed the medical records of patients with stage III NSCLC and ILD treated with curative-intent chemoradiotherapy as the first-line treatment at the Shizuoka Cancer Center between June 2009 and May 2014. Results: Of 37 patients, 17 (46%) developed AE of ILD worse than grade 3 within 1 year after the last irradiation. In univariate analysis, the incidence rate of AE of ILD was lower in patients with a non-usual interstitial pneumonia (UIP) pattern than in those with a UIP pattern. Multivariate analysis showed that ILD classification was significantly associated with the incidence of AE of ILD. The median overall survival (OS) durations in patients with a non-UIP pattern and a UIP pattern were 16.5 and 9.3 months, respectively. In univariate analysis, patients with a non-UIP pattern showed better survival. Multivariate analysis showed that ILD classification was a significant independent prognostic factor. Conclusion: The incidence of AE of ILD was high in patients with stage III NSCLC and ILD treated with chemoradiotherapy as the first-line treatment. However, diagnosis of a non-UIP pattern could predict lower risk of AE of ILD and longer OS durations.

[1]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[2]  D. Béliveau-Nadeau,et al.  Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. , 2016, Practical radiation oncology.

[3]  D. Lynch,et al.  Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease , 2024, Therapeutic advances in respiratory disease.

[4]  N. Inui,et al.  Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer , 2015, PloS one.

[5]  Zhi-rui Zhou,et al.  The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease , 2015, Medicine.

[6]  Sang Nam Lee,et al.  Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[7]  M. Endo,et al.  Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease , 2015, Cancer Chemotherapy and Pharmacology.

[8]  K. Togashi,et al.  Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  H. Yamashita,et al.  Radiation pneumonitis after stereotactic radiation therapy for lung cancer. , 2014, World journal of radiology.

[10]  Y. Korogi,et al.  Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. , 2013, Lung cancer.

[11]  K. Azuma,et al.  Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. , 2012, Oncology letters.

[12]  M. Bhargava,et al.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis , 2012, Reference Module in Biomedical Sciences.

[13]  Yukiko Nakamura,et al.  The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Masaaki Kawahara,et al.  Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Keitaro Matsuo,et al.  Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Akashi,et al.  Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. , 2008, Chest.

[17]  T. Shim,et al.  Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. , 2007, Chest.

[18]  G. Raghu,et al.  High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. , 2005, American journal of respiratory and critical care medicine.

[19]  T. King.  Clinical advances in the diagnosis and therapy of the interstitial lung diseases. , 2005, American journal of respiratory and critical care medicine.

[20]  R. Fisher,et al.  Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. , 2005, International Journal of Radiation Oncology, Biology, Physics.

[21]  D. Hansell,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[22]  I. Lax,et al.  The role of radiotherapy in treatment of stage I non-small cell lung cancer. , 2003, Lung cancer.

[23]  G. Ceresoli,et al.  Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  S. Tyldesley,et al.  Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. , 2001, International journal of radiation oncology, biology, physics.

[25]  N. Saijo,et al.  Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. , 2001, International journal of radiation oncology, biology, physics.

[26]  N. P. Rowell,et al.  Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review , 2000, Thorax.

[27]  G. Raghu,et al.  The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. , 1999, Chest.

[28]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Hayakawa,et al.  Risk factors for severe radiation pneumonitis in lung cancer. , 1999, Japanese journal of clinical oncology.

[30]  G. Sibley.  Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma , 1998, Cancer.

[31]  S. Anthony,et al.  Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer , 1996, Annals of Internal Medicine.

[32]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[33]  N. Sanuki,et al.  Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. , 2012, Journal of radiation research.

[34]  A. Piermattei,et al.  Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. , 2010, International journal of radiation oncology, biology, physics.

[35]  L. Tanoue.  Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study , 2010 .

[36]  H. Ohmatsu,et al.  Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. , 2001, European journal of cancer.

[37]  W. Travis,et al.  Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. , 2000, The American journal of surgical pathology.

[38]  Y. Tamaki,et al.  Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  J. Pignon,et al.  Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta‐analysis , 1996, Cancer.